Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Jardiance (empagliflozin) and Actos (pioglitazone) are both medications used to manage Type 2 diabetes, but they work differently and have distinct characteristics. Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by causing your body to excrete excess sugar through urine. It also has benefits for heart failure and chronic kidney disease. Actos, on the other hand, is a thiazolidinedione that improves your body's ability to use insulin. Jardiance is taken once daily and is currently only available as a brand-name medication, with generics expected after 2025. Actos is also taken once daily and is available in generic form. Jardiance can cause urinary tract and yeast infections, while Actos may lead to weight gain, fluid build-up, and an increased risk of bladder cancer and bone fractures. Additionally, Jardiance is not recommended during the second and third trimesters of pregnancy, whereas Actos is not suitable for those with uncontrolled heart failure or bladder cancer.
Pioglitazone (Actos) is an oral medication used to treat Type 2 diabetes in adults, along with diet and exercise. It's a thiazolidinedione, which works by helping your body respond better to insulin. This medication is taken by mouth once a day and is available in both brand and generic forms. Side effects include headache, swelling in the body, and weight gain. There's also a serious warning that it can cause or worsen heart failure.
Indications of Jardiance vs. Actos
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)